Extended-range EVs, or EREVs, serve to split the difference between a plug-in hybrid and a full-on battery-powered electric ...

Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.

Ideaya is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028. Click ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.

SentinelOne is making a major push this year around AI-powered SIEM, as well as cloud and data security, Channel Chief Brian ...

FIBRONEER™-ILD was a double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nerandomilast ...

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine. New Drug Application (NDA) Submission Expected in the ...

We recently published a list of 10 Best Software Infrastructure Stocks to Buy According to Analysts. In this article, we are ...

From that perspective, Palo Alto Networks trades at essentially half the valuation of CrowdStrike.

BlackBerry acquired Cylance, which harnesses artificial intelligence (AI) to help power its security offerings, in 2019. That deal saw it pay $1.4 billion in cash, in addition to unvested employee ...

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.